A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Categories (click each to see list of all clinical trials associated with that category): Lung/Thoracic
Current Status: Open to accrual
Phase: III
Principal Investigator: Marr, Alissa
Contact Information:
Debbie Vidlak
dvidlak@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT04396860?term=NCT04396860&draw=2&rank=1#eligibility
Summary